公开(公告)号：US20220235033A1

公开(公告)日：2022-07-28

申请号：US17613988

申请日：2020-05-26

Applicant: Merck Sharp & Dohme Corp.

Inventor： Jacqueline D. Hicks ,  John S. Debenham ,  Amjad Ali ,  Lan Wei ,  Tianying Jian ,  Dexi Yang ,  Anthony K. Ogawa ,  Wenlang Fu ,  Matthew Lombardo ,  Rongze Kuang ,  Meng Yang ,  Sung-Sau So ,  Kenneth Ellsworth ,  Peter Nizner ,  Daniel A. Tatosian ,  Robert R. Wilkening ,  Jun Wang

IPC: C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

公开(公告)号：US11014920B2

公开(公告)日：2021-05-25

申请号：US16461825

申请日：2017-11-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： Jacqueline D. Hicks ,  Brian Alexander McKittrick ,  Brent R. Whitehead ,  Matthew Lombardo ,  Xiaoqing Han ,  Jerry A. Taylor ,  Hong Dong Chu ,  Sung-Sau So ,  Peter Orth ,  Zhicai Wu

IPC: C07D417/14 ,  A61P7/02 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

公开(公告)号：US20210040127A1

公开(公告)日：2021-02-11

申请号：US16977253

申请日：2019-03-08

Applicant: Merck Sharp & Dohme Corp.

Inventor： Abdelghani Abe Achab ,  Matthew L. Childers ,  Jared N. Cumming ,  Christian A. Fischer ,  Symon Gathiaka ,  Hakan Gunaydin ,  Charles A. Lesburg ,  Derun Li ,  Min Lu ,  Anandan Palani ,  Rachel L. Palte ,  Qinglin Pu ,  David L. Sloman ,  Sung-Sau So ,  Chunrui Sun ,  Hongjun Zhang

IPC: C07F5/02 ,  C07K16/28

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

公开(公告)号：US20200262831A1

公开(公告)日：2020-08-20

申请号：US16461825

申请日：2017-11-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： Jacqueline D. Hicks ,  Brian Alexander McKittrick ,  Brent R. Whitehead ,  Matthew Lombardo ,  Xiaoqing Han ,  Jerry A. Taylor ,  Hong Dong Chu ,  Sung-Sau So ,  Peter Orth ,  Zhicai Wu

IPC: C07D417/14 ,  A61P7/02 ,  C07D417/12 ,  C07D409/12 ,  C07D409/14 ,  C07D401/12

Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

公开(公告)号：US10011585B2

公开(公告)日：2018-07-03

申请号：US15329635

申请日：2015-07-23

Applicant: Merck Sharp & Dohme Corp.

Inventor： Weiguo Liu ,  Scott D Edmondson ,  Zhuyan Guo ,  Alan Hruza ,  Sung-Sau So ,  Wanying Sun ,  Amjad Ali ,  Rongze Kuang ,  Ying-Duo Gao ,  Anthony K Ogawa

IPC: C07D401/06 ,  C07D401/14

CPC classification number: C07D401/06 ,  C07D401/14

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

公开(公告)号：US09975874B2

公开(公告)日：2018-05-22

申请号：US15329609

申请日：2015-07-23

Applicant: Merck Sharp & Dohme Corp.

Inventor： Eric Mertz ,  Scott D. Edmondson ,  Alan Hruza ,  Jiafang He ,  Sung-Sau So ,  Amjad Ali ,  Ying-Duo Gao

IPC: C07D401/10 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D401/10 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

公开(公告)号：US20170240524A1

公开(公告)日：2017-08-24

申请号：US15329609

申请日：2015-07-23

Applicant: Merck Sharp & Dohme Corp.

Inventor： Eric Mertz ,  Scott D. Edmondson ,  Alan Hruza ,  Jiafang He ,  Sung-Sau So ,  Amjad Ali ,  Ying-Duo Gao

IPC: C07D401/10 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D401/10 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention provides a compound of Formula (I) (Formula(I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.